Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study.
Martin CA, Jenkins DR, Minhas JS, Gray LJ, Tang J, Williams C, Sze S, Pan D, Jones W, Verma R, Knapp S, Major R, Davies M, Brunskill N, Wiselka M, Brightling C, Khunti K, Haldar P, Pareek M; Leicester COVID-19 consortium. Martin CA, et al. Among authors: pan d. EClinicalMedicine. 2020 Aug;25:100466. doi: 10.1016/j.eclinm.2020.100466. Epub 2020 Jul 17. EClinicalMedicine. 2020. PMID: 32840492 Free PMC article.
Awake prone positioning in COVID-19.
Koeckerling D, Barker J, Mudalige NL, Oyefeso O, Pan D, Pareek M, Thompson JP, Ng GA. Koeckerling D, et al. Among authors: pan d. Thorax. 2020 Oct;75(10):833-834. doi: 10.1136/thoraxjnl-2020-215133. Epub 2020 Jun 16. Thorax. 2020. PMID: 32546571 Review. No abstract available.
The impact of ethnicity on clinical outcomes in COVID-19: A systematic review.
Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divall P, Williams CM, Oggioni MR, Squire IB, Nellums LB, Hanif W, Khunti K, Pareek M. Pan D, et al. EClinicalMedicine. 2020 Jun 3;23:100404. doi: 10.1016/j.eclinm.2020.100404. eCollection 2020 Jun. EClinicalMedicine. 2020. PMID: 32632416 Free PMC article.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Among authors: pan d. Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9. Lancet Infect Dis. 2022. PMID: 35550261 Free PMC article. Clinical Trial.
4,182 results